Facio obtains funding from the Dutch FSHD Foundation 

Facio Therapies has received support from the FSHD Stichting (“Dutch FSHD Foundation”) for a total of €100,000 (about 110,000 USD) for its drug discovery program towards a causal therapy for FSHD. 

Facio will use the proceeds from this convertible loan for its ongoing drug discovery program. This program is running in close collaboration with partner Evotec and aims at identifying small molecules with a positive effect on SMCHD1 and DUX4 activity and as such have the potential to be developed into a therapeutic that tackles the cause and stops the progression of FSHD. 

“We are pleased to contribute to Facio’s efforts of finding a treatment for FSHD. We believe in their road to therapy and above all, we are thrilled by Facio’s alignment with the FSHD community,” said Robert Staartjes, treasurer of the Dutch FSHD Foundation. “We believe in solutions!” 

“We are very grateful for this contribution from the Dutch Foundation. This, and last year’s investment from the Australian FSHD Global Research Foundation, underlines Facio’s principle of being by and for people with FSHD,” said Facio’s Managing Director David Dasberg. “We strongly believe in allied forces and the increasing support from the FSHD community truly sustains our approach to overcome FSHD together.” 

About the FSHD Stichting
The Dutch FSHD Foundation stimulates, facilitates, and financially supports solid scientific research into the causes of FSHD, in order to find treatments and develop solutions that help improve patients’ quality of life. For more information, please visit FSHD Stichting